Advertisement

Topics

Vernalis shares slide after latest FDA rejection

08:53 EDT 7 Aug 2017 | pharmaphorum

Shares in UK pharma Vernalis slid more than 15% after the US regulator rejected its cough and cold treatment, known as CCP-08. The FDA sent Vernalis a dreaded Complete Response Letter (CRL) rejecting CCP-08, although the company gave no further d...

Original Article: Vernalis shares slide after latest FDA rejection

NEXT ARTICLE

More From BioPortfolio on "Vernalis shares slide after latest FDA rejection"

Quick Search
Advertisement